Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma
16 août 2023 07h00 HE
|
AEON Biopharma
The 7,380,394 AEON shares reflected in the Form 4 filed on August 14th were transferred to limited partners of Strathspey Crown Strathspey Crown did not sell any AEON shares to the public as part...
AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
24 juil. 2023 07h00 HE
|
AEON Biopharma
Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEON and AEON WS, respectively Phase 2 topline data with ABP-450 for the...
AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination
30 juin 2023 08h00 HE
|
AEON Biopharma
IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin...
AEON Biopharma to Host Key Opinion Leader Webinar on Past, Present, and Potential Future Treatments for Migraine on February 24th
14 févr. 2023 08h00 HE
|
AEON Biopharma
IRVINE, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin...
AEON Biopharma Confirms Development Strategy and Timelines for ABP-450 Unaffected by Korean Court Ruling on Dispute Between Medytox and Daewoong Pharmaceutical
10 févr. 2023 22h24 HE
|
AEON Biopharma
IRVINE, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin...
AEON Biopharma and Priveterra Acquisition Corp. Announce Additional Capital Commitment from Existing Investors for at Least $20 Million
10 janv. 2023 07h30 HE
|
AEON Biopharma
IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin...
AEON Biopharma Completes Enrollment in Phase 2 Trial of ABP-450 for Preventive Treatment of Episodic Migraine
21 déc. 2022 07h30 HE
|
AEON Biopharma
– Topline data expected to be announced in 2H 2023 – – Topline data from the Company’s Phase 2 trial in preventive treatment of chronic migraine expected to be announced in 1H 2024 – IRVINE,...
AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology
13 déc. 2022 07h00 HE
|
AEON Biopharma
– Positive topline data from Phase 2 study of ABP-450 for cervical dystonia announced in September 2022 – – Topline data from Phase 2 study of ABP-450 for episodic migraine expected in Q4 2023 – ...
AEON Biopharma Reports Positive Topline Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia
23 sept. 2022 07h00 HE
|
AEON Biopharma
– Phase 2 trial met primary and secondary endpoints with statistical significance in reducing signs and symptoms associated with cervical dystonia (CD) in adults – – All three dosing arms...
AEON Biopharma Raises $30 Million from Insiders
03 août 2022 07h30 HE
|
AEON Biopharma
IRVINE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a private clinical-stage biopharmaceutical company focused on the development of its proprietary...